Concepedia

Publication | Open Access

Drotrecogin Alfa (Activated) in Adults with Septic Shock

DOIFull Paper Access

1.3K

Citations

32

References

2012

Year

V. Marco Ranieri, Bruce Thompson, Philip S. Barie, Jean-François Dhainaut, Ivor S. Douglas, Simon Finfer, Bengt Gårdlund, John C. Marshall, Andrew Rhodes, Antonio Artigas,
New England Journal of Medicine

Abstract

DrotAA did not significantly reduce mortality at 28 or 90 days, as compared with placebo, in patients with septic shock. (Funded by Eli Lilly; PROWESS-SHOCK ClinicalTrials.gov number, NCT00604214.).

References

YearCitations

Page 1